[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342818-105":59,"doc-detail-342818-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nivolumab-for-mismatch-repair-deficient-or-hypermutated-gynecologic-cancers-a-phase-2-trial-with-biomarker-analyses","Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses","","Nivolumab, an anti–PD-1 therapy, is approved for gynecologic cancers with DNA mismatch repair deficiency (dMMR), yet reliable predictors of benefit remain unclear. A single-arm phase 2 study enrolled 35 patients with dMMR uterine or ovarian cancer. Co-primary endpoints were objective response rate (ORR) and progression-free survival at 24 weeks (PFS24), both met. Exploratory biomarker analyses linked dysfunctional/terminally dysfunctional CD8+PD-1+ T-cell states and PD-L1+ cell interactions to PFS24, and PFS24 associated with MEGF8 or SETD1B somatic mutations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nivolumab-for-mismatch-repair-deficient-or-hypermutated-gynecologic-cancers-a-phase-2-trial-with-biomarker-analyses/342818/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nivolumab-for-mismatch-repair-deficient-or-hypermutated-gynecologic-cancers-a-phase-2-trial-with-biomarker-analyses/342818.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What were the co-primary endpoints of this phase 2 nivolumab study?","Question",{"text":112,"@type":113},"The co-primary endpoints were objective response rate (ORR) and progression-free survival at 24 weeks (PFS24).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did patients respond to nivolumab based on ORR and PFS24?",{"text":117,"@type":113},"ORR was 58.8% and the PFS24 rate was 64.7%, meeting the pre-specified endpoints.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biomarker features were independently associated with PFS24?",{"text":121,"@type":113},"Presence of dysfunctional (CD8+PD-1+) or terminally dysfunctional (CD8+PD-1+TOX+) T cells, together with interactions involving PD-L1+ cells, were independently associated with PFS24, and PFS24 was also associated with MEGF8 or SETD1B somatic mutations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342818,1790814550,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","| nature medicine |  |  | |\n| --- | --- | --- | --- |\n| Article [https://doi.org/10.1038/s41591-024-02942-7](https://doi.org/10.1038/s41591-024-02942-7) |  |  |  |\n| Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses |  |  |  |\n| Received: 12 July 2023\u003Cbr>Accepted: 25 March 2024\u003Cbr>Published online: 23 April 2024  Check for updates | A list of authors and their affiliations appears atthe end of the paper\u003Cbr>Programmed death-1 (PD-1) inhibitors are approved for therapy of gynecologic cancers with DNA mismatch repair deficiency (dMMR), although predictors of response remain elusive. We conducted a single-arm phase 2 study of nivolumabin 35 patients with dMMR uterine or ovarian cancers. Co-primary endpoints included objective response rate (ORR) and progression-free survival at 24 weeks (PFS24). Secondary endpoints included overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety. Exploratory endpoints included biomarkers and molecular correlates of response. The ORR was 58.8%(97.5% confidence interval (CI): 40.7–100%), and the PFS24 rate was 64.7%(97.5% one-sided CI: 46.5–100%), meeting the pre-specified endpoints. The DCR was 73.5%(95% CI: 55.6–87.1%). Atthe median follow-up of 42.1 months (range, 8.9–59.8 months), median OS was not reached. One-year OS rate was 79%(95% CI: 60.9–89.4%). Thirty-two patients (91%) hada treatment-related adverse event (TRAE), including arthralgia (n = 10, 29%), fatigue (n = 10, 29%), pain (n = 10, 29%) and pruritis (n = 10, 29%); most were grade 1 or grade 2. Ten patients (29%) reported a grade 3 or grade 4 TRAE; no grade 5 events occurred.\u003Cbr>Exploratory analyses show that the presence of dysfunctional (CD8+PD-1+) or terminally dysfunctional (CD8+PD-1+TOX+) T cells and their interaction with programmed death ligand-1 (PD-L1)+ cells were independently associated with PFS24. PFS24 was associated with presence of MEGF8 or SETD1B somatic mutations. This trial met its co-primary endpoints (ORRand PFS24) early, and our findings highlight several genetic and tumor microenvironment parameters associated with response to PD-1 blockade indMMR cancers, generating rationale for their validation in larger cohorts. ClinicalTrials.gov identifier: NCT03241745. |  |  |\n| Endometrial cancer and ovarian cancer are among the most common and fatal malignancies for women in the United States, with an estimated 13,030 and 13,270 deaths, respectively, in 2023 (ref. 1). Inpatients with advanced or recurrent disease, the survival benefit with |  | single-agent chemotherapy or hormone therapy is modest at best2–4. Work from The Cancer Genome Atlas (TCGA) has demonstrated that, within endometrial cancer, there are four distinct molecular subtypes: POLE ultramutated, microsatellite instability (MSI) hypermutated, |  |\n\ne-mail: [friedmac@mskcc.org](friedmac@mskcc.org); [dmitriy.zamarin@mssm.edu](dmitriy.zamarin@mssm.edu)  \ncopy number-low and copy number-high5. These molecular subtypes are associated with progression-free survival (PFS) and overall survival (OS), with POLE ultramutated tumors having the best outcomes and copy number-high tumors having the worst. Approximately 30% to 35% of endometrial cancers are classified as MSI or DNA mismatch repair deficient (dMMR)5,6. MSI leads to the accumulation of mismatches, insertionsand deletionsin repeat sequences of DNA—and, thus, amutation burden approximately 10-fold greater than microsatellite stable (MSS) tumors. Although most common inendometrioid or clear cell histologies, a subset of ovarian cancers also demonstrates dMMR7. Based on findings from five single-arm studies that reported durable responsesin approximately 50% of treated patients, pembrolizumab, an anti-programmed death-1 (PD-1) monoclonal antibody, was granted accelerated approval by the US Food and Drug Administration (FDA) asthe first tissue-site-agnostic agent inpatients with MSI-high (MSI-H) or dMMR cancers th","cbCaijD9g3Aqe2Yb","https://ap.wps.com/l/cbCaijD9g3Aqe2Yb","pdf",5226470,26,"English","# Study outcomes\n## Primary endpoints\n## Secondary and exploratory endpoints\n# Biomarker and molecular correlates\n## T-cell functional states\n## Somatic mutations","[{\"question\":\"What were the co-primary endpoints of this phase 2 nivolumab study?\",\"answer\":\"The co-primary endpoints were objective response rate (ORR) and progression-free survival at 24 weeks (PFS24).\"},{\"question\":\"How did patients respond to nivolumab based on ORR and PFS24?\",\"answer\":\"ORR was 58.8% and the PFS24 rate was 64.7%, meeting the pre-specified endpoints.\"},{\"question\":\"Which biomarker features were independently associated with PFS24?\",\"answer\":\"Presence of dysfunctional (CD8+PD-1+) or terminally dysfunctional (CD8+PD-1+TOX+) T cells, together with interactions involving PD-L1+ cells, were independently associated with PFS24, and PFS24 was also associated with MEGF8 or SETD1B somatic mutations.\"}]","Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses | PDF",1790048306,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c35c79b12c3e4ccecb7454fd1eb3c228.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c33fbc8a9b16785fe5f392939fd150a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfb51489066d348dccf5936c206d6ff0.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9c2789c601aa988bddc1bdec8043c88.webp",980,1301]